Cytokinetics (NASDAQ:CYTK) used its presentation at Citi’s Life Sciences Conference to highlight the recent U.S. approval of its first drug, Myqorzo, and to preview an upcoming Phase 3 readout in non- ...

Cytokinetics (NASDAQ:CYTK) executives told investors at the Barclays healthcare conference that the company’s U.S. launch of ...

ACACIA-HCM is a Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of aficamten compared to placebo on health-related quality of life in ...

Many drugs available and in development work by targeting proteins, an approach that comes with limitations. For one, proteins are not the root cause of disease, said Samir Ounzain, co-founder and CEO ...

SOUTH SAN FRANCISCO, Calif., May 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that additional data arising from two analyses from SEQUOIA-HCM, (Safety, Efficacy, and ...

– Topline Phase 2 data from the IMPROVE-ISCHEMIA clinical trial in Stable Angina also anticipated in 4Q 2023 – BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, ...

– Results support initiation of the Phase 3 FORTITUDE-HCM clinical trial of ninerafaxstat in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) and its continued development ...

MYQORZO® (aficamten) is an investigational selective, small molecule cardiac myosin inhibitor discovered following an extensive chemical optimization program that was conducted with careful attention ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 ...